Medicine
Endothelial Dysfunction in Preeclampsia and Therapeutic Targets
Quick fact
In preeclampsia, the placenta produces excessive amounts of a protein called sFlt-1 that 'soaks up' VEGF, starving the mother's blood vessel lining and causing widespread dysfunction.
Why this is interesting
Preeclampsia is a leading cause of maternal death worldwide, yet its cause was a mystery for centuries. Now, we know it begins in the placenta but wreaks havoc on blood vessels everywhere.
Read the full explanation
Understanding Endothelial Dysfunction in Preeclampsia and Therapeutic Targets
Imagine your blood vessels as a network of flexible tubes. The inner lining, called the endothelium, is crucial for controlling blood pressure and preventing clotting. In a healthy pregnancy, the placenta and the mother's blood vessels communicate properly. But in preeclampsia, the placenta becomes stressed (often due to poor blood flow) and releases 'danger signals'—proteins like sFlt-1 (soluble fms-like tyrosine kinase-1) and sEng (soluble endoglin). These proteins act like sponges, absorbing growth factors that the endothelium needs to stay healthy and flexible. Without these growth factors, the endothelium becomes dysfunctional: it can't dilate properly, it starts leaking fluid (causing swelling and protein in urine), and it becomes pro-coagulant. This leads to high blood pressure and damage to organs like the kidneys, liver, and brain.
A deeper explanation
The core mechanism is an angiogenic imbalance. Normally, pro-angiogenic factors like VEGF (vascular endothelial growth factor) and PlGF (placental growth factor) promote endothelial survival and vasodilation. In preeclampsia, the ischemic placenta overproduces sFlt-1 and sEng. sFlt-1 binds to VEGF and PlGF, preventing them from signaling through their receptors on the endothelium. This leads to decreased nitric oxide production, a potent vasodilator, and increased endothelin-1, a potent vasoconstrictor. The result is a shift toward vasoconstriction and inflammation. Therapeutic targets aim to restore this balance: antibodies to sFlt-1, recombinant PlGF, or agents that enhance endothelial function (like statins or phosphodiesterase inhibitors). By restoring the angiogenic balance, we can potentially treat the cause, not just the symptoms, of preeclampsia.